Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

BSH 2018 | Updates in CML: recent trials and novel agents

Susanne Saussele • 16 Apr 2018

BSH 2018

Chronic Myeloid Leukemia Leukemia Asciminib Dasatinib Imatinib Nilotinib Ponatinib

EURO-SKI

Highlights of promising clinical trials of novel agents for chronic myeloid leukemia (CML) are overviewed here by Susanne Saussele, MD, of the University of Mannheim, Mannheim, Germany. Discussed are Phase I trial of the BCR-ABL inhibitor ABL001 (NCT02081378), and the use of ponatinib as a second line therapy. Prof. Saussele herself is working on the EURO-SKI trial (NCT01596114) in individuals with late relapse CML, partially assessing the effects of halting treatment with imatinib, nilotinib and dasatinib, and she holds promise for the upcoming results. This interview took place at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK.

The importance of better selecting patients with CML who are eligible for treatment discontinuation

Susanne Saussele • 22 Oct 2022

The impact of ACA in CML & the importance of monitoring these patients

Susanne Saussele • 22 Oct 2022

Examples of challenging scenarios for TFR in CML & how to manage them

Susanne Saussele • 22 Oct 2022

Antibody responses to COVID-19 vaccines in patients with hematological malignancies

Susanne Saussele • 11 Dec 2021

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024